These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 47287)

  • 1. [Endocrinological principles of conservative therapy for prostatic adenoma].
    Altwein JE; Orestano F
    Dtsch Med Wochenschr; 1975 Mar; 100(12):626-9. PubMed ID: 47287
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medical therapy of benign prostatic hyperplasia: cyproterone acetate vs gestonorone caproate].
    Di Silverio F
    Minerva Urol Nefrol; 1986; 38(2):163-71. PubMed ID: 2428120
    [No Abstract]   [Full Text] [Related]  

  • 3. [Conservative treatment of benign prostatic hyperplasia (author's transl)].
    Schoenenberger A; Hauri D
    Ther Umsch; 1982 Apr; 39(4):260-7. PubMed ID: 6179177
    [No Abstract]   [Full Text] [Related]  

  • 4. Testosterone metabolism in benign prostatic hypertrophy: in vivo studies of gestonorone caproate and cyproterone acetate.
    Orestano F; Altwein JE
    Br J Urol; 1976 Dec; 48(6):485-91. PubMed ID: 64267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone metabolism in benign prostatic hypertrophy. Suppression by diethylstilbestrol and gestonorone capronate.
    Orestano F; Klose K; Rubin A; Knapstein P; Altwein JE
    Invest Urol; 1974 Sep; 12(2):151-6. PubMed ID: 4137236
    [No Abstract]   [Full Text] [Related]  

  • 6. [Gestonorone therapy of prostatic adenoma].
    Lopatkin N; Darenkow A; Sahmatow J; Tankó A; Ignaschin N; Warentsow G
    Acta Chir Acad Sci Hung; 1980; 21(4):271-8. PubMed ID: 6175122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of benign prostatic hypertrophy with gestonorone caproate].
    Baranowska B; Kuzaka B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):999-1003. PubMed ID: 6209689
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of treating prostatic adenoma with Depostat].
    Darenkov AF; Zakhvatov IuM; Tanko A; Ignashin NS; Varentsov GI
    Urol Nefrol (Mosk); 1980; (5):34-7. PubMed ID: 6158780
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recent results of prostatic adenoma research].
    Kaufmann J
    Z Urol Nephrol; 1975 Nov; 68(11):. PubMed ID: 58501
    [No Abstract]   [Full Text] [Related]  

  • 10. Depostat for benign prostatic hyperplasia?
    Drug Ther Bull; 1973 Sep; 11(19):75-6. PubMed ID: 4130364
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
    Kanimoto Y; Okada K
    Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Depostat in prostatic adenoma on the ground of clinical and sphincterotonometric studies.
    Makrigiannis D; Gaca A
    Int Urol Nephrol; 1971; 3(1):21-9. PubMed ID: 4117491
    [No Abstract]   [Full Text] [Related]  

  • 13. [Monitoring the effectiveness of conservative treatment of benign prostatic hypertrophy by means of uroflowmetry].
    Tunn U; Senge T
    Z Urol Nephrol; 1978 Aug; 71(8):521-8. PubMed ID: 83057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
    Iguchi H; Ikeuchi T; Kai Y; Yoshida H
    Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mode of action of progesterone, gestonorone capronate (Depostat) and cyproterone acetate (Androcur) on the metabolism of testosterone in human prostatic adenoma: in vitro and in vivo investigations.
    Orestano F; Altwein JE; Knapstein P; Bandhauer K
    J Steroid Biochem; 1975 Jun; 6(6):845-51. PubMed ID: 1177428
    [No Abstract]   [Full Text] [Related]  

  • 16. [Influence of gestonoron-capronate (GC) upon uptake and metabolism of H3-testosteron in benign prostatic hypertrophy (BPH): in vivo-experiments (author's transl)].
    Orestano F; Bandhauer K; Altwein JE
    Urologe A; 1974 Nov; 13(6):289-92. PubMed ID: 4141158
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of benign enlargement of the prostate with nor progesterone caproate (primostat).
    Subbiah N; Mortensen J
    Aust N Z J Surg; 1973 Feb; 42(3):304-7. PubMed ID: 4129814
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current therapy of benign prostatic hypertrophy].
    Rist M
    Schweiz Rundsch Med Prax; 1986 Jul; 75(29):875-6. PubMed ID: 2426754
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiandrogens and prostatic tumours (experimental base and clinical use).
    Neumann R; Schenck B; Senge T; Richter KD
    Prog Clin Biol Res; 1976; 6():169-88. PubMed ID: 66688
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study.
    Meiraz D; Margolin Y; Lev-Ran A; Lazebnik J
    Urology; 1977 Feb; 9(2):144-8. PubMed ID: 65818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.